New drug aims to unclog lungs in chronic bronchiectasis patients
NCT ID NCT07547436
First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times
Summary
This study tests an experimental drug called SAR445399 in 70 adults aged 18-80 with non-cystic fibrosis bronchiectasis, a lung condition causing mucus buildup and infections. Participants receive either the drug or a placebo for 24 weeks to see if it reduces mucus plugs seen on CT scans. The goal is to improve breathing and reduce flare-ups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-CYSTIC FIBROSIS BRONCHIECTASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Advanced Pulmonary Research Institute- Site Number : 8400001
Loxahatchee Groves, Florida, 33470, United States
-
Clinical Research Associates of Central Pennsylvania- Site Number : 8400006
DuBois, Pennsylvania, 15801, United States
-
Hull and Hull Medical Specialists- Site Number : 8400002
Plantation, Florida, 33324, United States
-
Pulmonary Associates - Phoenix - East McDowell Road- Site Number : 8400008
Phoenix, Arizona, 85006, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A vibrating vest may help children with damaged lungs breathe easier
- Can a new biologic drug delay dangerous lung Flare-Ups?
- Inhaled experimental drug targets tough lung infections
- New drug trial aims to tame chronic lung infections
- Scientists develop risk score to forecast bronchiectasis attacks
- 500 patients to test if daily azithromycin keeps bronchiectasis attacks at bay